Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Procyclidine 5mg tablets
0409020S0AAAEAE
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | 102,492 |
|
Kemadrin 5mg tablets
0409020S0BCAAAE
|
Kemadrin | Procyclidine hydrochloride | Central Nervous System | 53,107 |
|
Procyclidine 5mg/5ml oral solution sugar free
0409020S0AAAHAH
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | 3,264 |
|
Procyclidine 2.5mg/5ml oral solution sugar free
0409020S0AAAGAG
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | 1,592 |
|
Procyclidine 10mg/2ml solution for injection ampoules
0409020S0AAACAC
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | 29 |
|
Arpicolin 2.5mg/5ml oral solution
0409020S0BBAAAG
|
Arpicolin | Procyclidine hydrochloride | Central Nervous System | No data available |
|
Arpicolin 5mg/5ml oral solution
0409020S0BBABAH
|
Arpicolin | Procyclidine hydrochloride | Central Nervous System | No data available |
|
Kemadrin 10mg/2ml solution for injection ampoules
0409020S0BCABAC
|
Kemadrin | Procyclidine hydrochloride | Central Nervous System | No data available |
|
Muscinil 5mg tablets
0409020S0BDAAAE
|
Muscinil | Procyclidine hydrochloride | Central Nervous System | No data available |
|
Procyclidine 2.5mg/5ml oral liquid
0409020S0AAAKAK
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | No data available |
|
Procyclidine 5mg/5ml oral liquid
0409020S0AAAJAJ
|
Procyclidine hydrochloride | Procyclidine hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.